Activation of HBP promotes the proliferation of lung cancer cells, and the inhibition of enzymes related to HBP such as glutamine fructose-6-phosphate amidotransferase 1 (GFAT1) reduces programmed death ligand 1 (PD-L1) levels and, therefore, the progression of lung cancer. Here, GFPT1 is linked to lung carcinoma.